Meeting
2021 Gastrointestinal Cancers Symposium
Conversion from unresectable to resectable liver metastases in real-world patients with liver-only metastatic colorectal cancer (mCRC) treated with FOLFOXIRI plus bevacizumab: The Conversion trial.
Authors
Shahid Ahmed
University of Saskatchewan, Saskatoon, SK, Canada
Shahid Ahmed , Deborah Anderson , Haji I. Chalchal , Lynn Dwernychuk , Dilip Gill , Josh Gitlin , Austin Hammond , Rani Kanthan , Duc Le , June Lim , Rajan Rakheja , Nazmi Sari , Franco Vizeacoumar , Adnan Zaidi , Michael Moser
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session: Colorectal Cancer
Track
Colorectal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03401294
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr TPS147)
DOI
10.1200/JCO.2021.39.3_suppl.TPS147
Abstract #
TPS147
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
FOLFOXIRI with or without bevacizumab as first-line treatment for unresectable liver-only metastatic colorectal cancer patients with RAS mutation-type.
First Author: Yanhong Deng
Poster
2020 Gastrointestinal Cancers Symposium
Rate of conversion from unresectable to resectable metastatic colorectal cancer (mCRC) in real-world patients (RWP) treated with FOLFIXIRI ± bevacizumab: A population-based retrospective cohort study.
First Author: Tayyaba Bhatti
Poster
2013 ASCO Annual Meeting
Randomized, phase II study of bevacizumab with mFOLFOX6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: Resectability and safety in OLIVIA.
First Author: Thomas Gruenberger
Poster
2018 ASCO Annual Meeting
Outcomes of oxaliplatin-based (Ox) chemotherapy (CT) on R0 resection of colonic liver metastases (CLM).
First Author: Nicholas Adam Bosma